カテゴリ： GlobalInfoResearch, 世界, 医療/バイオ

世界の慢性骨髄性白血病治療市場2022年：市場規模予測（～2028年）

■ 英語タイトル：Global Chronic Myeloid Leukemia Treatment Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028

調査会社GlobalInfoResearch社が発行したリサーチレポート（データ管理コード：GIR22NO19231）■ 発行会社/調査会社：GlobalInfoResearch
■ 商品コード：GIR22NO19231
■ 発行日：2022年11月（※2025年版があります。お問い合わせください。）
■ 調査対象地域：グローバル
■ 産業分野：医薬品
■ ページ数：109
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（注文後2-3日）
■ 販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,480 ⇒換算￥528,960見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD5,220 ⇒換算￥793,440見積依頼/購入/質問フォーム
Corporate User（同一法人内共有可）USD6,960 ⇒換算￥1,057,920見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※GlobalInfoResearch社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[世界の慢性骨髄性白血病治療市場2022年：市場規模予測（～2028年）]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

慢性骨髄性白血病治療市場レポートは、世界の市場規模、地域および国レベルの市場規模、セグメント市場の成長性、市場シェア、競争環境、販売分析、国内および世界の市場プレーヤーの影響、バリューチェーンの最適化、最近の動向、機会分析、市場成長の戦略的な分析、製品発売、地域市場の拡大などに関する情報を提供します。
GlobalInfoResearchの最新の調査によると、世界の慢性骨髄性白血病治療の市場規模は2021年のxxx米ドルから2028年にはxxx米ドルと推定され、xxx％の成長率で成長すると予想されます。

慢性骨髄性白血病治療市場は種類と用途によって区分されます。2017年～2028年において、量と金額の観点から種類別および用途別セグメントの売上予測データを提供します。この分析は、適格なニッチ市場をターゲットにすることでビジネスを拡大するのに役立ちます。

種類別セグメントは次をカバーします。
・錠剤、溶液、カプセル

用途別セグメントは次のように区分されます。
・病院調剤薬局、小売調剤薬局、オンライン調剤薬局

世界の慢性骨髄性白血病治療市場の主要な市場プレーヤーは以下のとおりです。
・Teva Pharmaceutical Industries Ltd、F. Hoffmann-La Roche Ltd.、Novartis AG、Bristol-Myers Squibb Company、Pfizer Inc.、Takeda Pharmaceutical Company Limited、Innovent Biologics, Inc.、Viatris Inc. (Mylan N.V.)、Lupin、IL-YANG PHARM CO. LTD.、Million Health Pharmaceuticals、Celon Labs

地域別セグメントは次の地域・国をカバーします。
・北米（米国、カナダ、メキシコ）
・ヨーロッパ（ドイツ、フランス、イギリス、ロシア、イタリア）
・アジア太平洋（日本、中国、韓国、インド、東南アジア、オーストラリア）
・南アメリカ（ブラジル、アルゼンチン、コロンビア）
・中東およびアフリカ（サウジアラビア、UAE、エジプト、南アフリカ）

本調査レポートの内容は計15章あります。
・第1章では、慢性骨髄性白血病治療製品の調査範囲、市場の概要、市場の成長要因・阻害要因、および市場動向について説明します。
・第2章では、主要な慢性骨髄性白血病治療メーカーの企業概要、2019年～2022年までの慢性骨髄性白血病治療の価格、販売量、売上、市場シェアを掲載しています。
・第3章では、主要な慢性骨髄性白血病治療メーカーの競争状況、販売量、売上、世界市場シェアが重点的に比較分析されています。
・第4章では、2017年～2028年までの地域別慢性骨髄性白血病治療の販売量、売上、成長性を示しています。
・第5、6章では、2017年～2028年までの慢性骨髄性白血病治療の種類別と用途別の市場規模、市場シェアと成長率を掲載しています。
・第7、8、9、10、11章では、2017年～2022年までの世界の主要国での販売量、売上、市場シェア、並びに2023年～2028年までの主要地域での慢性骨髄性白血病治療市場予測を収録しています。
・第12章では、主要な原材料、主要なサプライヤー、および慢性骨髄性白血病治療の産業チェーンを掲載しています。
・第13、14、15章では、慢性骨髄性白血病治療の販売チャネル、販売業者、顧客、調査結果と結論、付録、データソースなどについて説明します。

***** 目次(一部) *****

・市場概要
- 慢性骨髄性白血病治療の概要
- 種類別分析（2017年vs2021年vs2028年）：錠剤、溶液、カプセル
- 用途別分析（2017年vs2021年vs2028年）：病院調剤薬局、小売調剤薬局、オンライン調剤薬局
- 世界の慢性骨髄性白血病治療市場規模・予測
- 世界の慢性骨髄性白血病治療生産能力分析
- 市場の成長要因・阻害要因・動向
・メーカー情報（企業概要、製品概要、販売量、価格、売上）
- Teva Pharmaceutical Industries Ltd、F. Hoffmann-La Roche Ltd.、Novartis AG、Bristol-Myers Squibb Company、Pfizer Inc.、Takeda Pharmaceutical Company Limited、Innovent Biologics, Inc.、Viatris Inc. (Mylan N.V.)、Lupin、IL-YANG PHARM CO. LTD.、Million Health Pharmaceuticals、Celon Labs
・メーカー別市場シェア・市場集中度
・地域別市場分析2017年-2028年
・種類別分析2017年-2028年：錠剤、溶液、カプセル
・用途別分析2017年-2028年：病院調剤薬局、小売調剤薬局、オンライン調剤薬局
・慢性骨髄性白血病治療の北米市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：アメリカ、カナダ、メキシコなど
・慢性骨髄性白血病治療のヨーロッパ市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：ドイツ、イギリス、フランス、ロシア、イタリアなど
・慢性骨髄性白血病治療のアジア市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：中国、日本、韓国、インド、東南アジア、オーストラリアなど
・慢性骨髄性白血病治療の南米市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：ブラジル、アルゼンチンなど
・慢性骨髄性白血病治療の中東・アフリカ市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：サウジアラビア、トルコ、エジプト、南アフリカなど
・原材料および産業チェーン
・販売チャネル、流通業者・代理店、顧客リスト
・調査の結果・結論

The Chronic Myeloid Leukemia Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Chronic Myeloid Leukemia Treatment market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during forecast period 2022-2028. Hospital Pharmacies accounting for % of the Chronic Myeloid Leukemia Treatment global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Tablet segment is altered to a % CAGR between 2022 and 2028.
Global key manufacturers of Chronic Myeloid Leukemia Treatment include Teva Pharmaceutical Industries Ltd, F. Hoffmann-La Roche Ltd., Novartis AG, Bristol-Myers Squibb Company, and Pfizer Inc., etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Chronic Myeloid Leukemia Treatment market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Tablet
Solution
Capsule
Market segment by Application can be divided into
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
The key market players for global Chronic Myeloid Leukemia Treatment market are listed below:
Teva Pharmaceutical Industries Ltd
F. Hoffmann-La Roche Ltd.
Novartis AG
Bristol-Myers Squibb Company
Pfizer Inc.
Takeda Pharmaceutical Company Limited
Innovent Biologics, Inc.
Viatris Inc. (Mylan N.V.)
Lupin
IL-YANG PHARM CO. LTD.
Million Health Pharmaceuticals
Celon Labs
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Chronic Myeloid Leukemia Treatment product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Chronic Myeloid Leukemia Treatment, with price, sales, revenue and global market share of Chronic Myeloid Leukemia Treatment from 2019 to 2022.
Chapter 3, the Chronic Myeloid Leukemia Treatment competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Chronic Myeloid Leukemia Treatment breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2017 to 2028.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2017 to 2022.and Chronic Myeloid Leukemia Treatment market forecast, by regions, type and application, with sales and revenue, from 2023 to 2028.
Chapter 12, the key raw materials and key suppliers, and industry chain of Chronic Myeloid Leukemia Treatment.
Chapter 13, 14, and 15, to describe Chronic Myeloid Leukemia Treatment sales channel, distributors, customers, research findings and conclusion, appendix and data source.

*** レポート目次（コンテンツ）***

1 Market Overview
1.1 Chronic Myeloid Leukemia Treatment Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Chronic Myeloid Leukemia Treatment Revenue by Type: 2017 Versus 2021 Versus 2028
1.2.2 Tablet
1.2.3 Solution
1.2.4 Capsule
1.3 Market Analysis by Application
1.3.1 Overview: Global Chronic Myeloid Leukemia Treatment Revenue by Application: 2017 Versus 2021 Versus 2028
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.4 Global Chronic Myeloid Leukemia Treatment Market Size & Forecast
1.4.1 Global Chronic Myeloid Leukemia Treatment Sales in Value (2017 & 2021 & 2028)
1.4.2 Global Chronic Myeloid Leukemia Treatment Sales in Volume (2017-2028)
1.4.3 Global Chronic Myeloid Leukemia Treatment Price (2017-2028)
1.5 Global Chronic Myeloid Leukemia Treatment Production Capacity Analysis
1.5.1 Global Chronic Myeloid Leukemia Treatment Total Production Capacity (2017-2028)
1.5.2 Global Chronic Myeloid Leukemia Treatment Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Chronic Myeloid Leukemia Treatment Market Drivers
1.6.2 Chronic Myeloid Leukemia Treatment Market Restraints
1.6.3 Chronic Myeloid Leukemia Treatment Trends Analysis
2 Manufacturers Profiles
2.1 Teva Pharmaceutical Industries Ltd
2.1.1 Teva Pharmaceutical Industries Ltd Details
2.1.2 Teva Pharmaceutical Industries Ltd Major Business
2.1.3 Teva Pharmaceutical Industries Ltd Chronic Myeloid Leukemia Treatment Product and Services
2.1.4 Teva Pharmaceutical Industries Ltd Chronic Myeloid Leukemia Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2 F. Hoffmann-La Roche Ltd.
2.2.1 F. Hoffmann-La Roche Ltd. Details
2.2.2 F. Hoffmann-La Roche Ltd. Major Business
2.2.3 F. Hoffmann-La Roche Ltd. Chronic Myeloid Leukemia Treatment Product and Services
2.2.4 F. Hoffmann-La Roche Ltd. Chronic Myeloid Leukemia Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3 Novartis AG
2.3.1 Novartis AG Details
2.3.2 Novartis AG Major Business
2.3.3 Novartis AG Chronic Myeloid Leukemia Treatment Product and Services
2.3.4 Novartis AG Chronic Myeloid Leukemia Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4 Bristol-Myers Squibb Company
2.4.1 Bristol-Myers Squibb Company Details
2.4.2 Bristol-Myers Squibb Company Major Business
2.4.3 Bristol-Myers Squibb Company Chronic Myeloid Leukemia Treatment Product and Services
2.4.4 Bristol-Myers Squibb Company Chronic Myeloid Leukemia Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5 Pfizer Inc.
2.5.1 Pfizer Inc. Details
2.5.2 Pfizer Inc. Major Business
2.5.3 Pfizer Inc. Chronic Myeloid Leukemia Treatment Product and Services
2.5.4 Pfizer Inc. Chronic Myeloid Leukemia Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6 Takeda Pharmaceutical Company Limited
2.6.1 Takeda Pharmaceutical Company Limited Details
2.6.2 Takeda Pharmaceutical Company Limited Major Business
2.6.3 Takeda Pharmaceutical Company Limited Chronic Myeloid Leukemia Treatment Product and Services
2.6.4 Takeda Pharmaceutical Company Limited Chronic Myeloid Leukemia Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7 Innovent Biologics, Inc.
2.7.1 Innovent Biologics, Inc. Details
2.7.2 Innovent Biologics, Inc. Major Business
2.7.3 Innovent Biologics, Inc. Chronic Myeloid Leukemia Treatment Product and Services
2.7.4 Innovent Biologics, Inc. Chronic Myeloid Leukemia Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8 Viatris Inc. (Mylan N.V.)
2.8.1 Viatris Inc. (Mylan N.V.) Details
2.8.2 Viatris Inc. (Mylan N.V.) Major Business
2.8.3 Viatris Inc. (Mylan N.V.) Chronic Myeloid Leukemia Treatment Product and Services
2.8.4 Viatris Inc. (Mylan N.V.) Chronic Myeloid Leukemia Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.9 Lupin
2.9.1 Lupin Details
2.9.2 Lupin Major Business
2.9.3 Lupin Chronic Myeloid Leukemia Treatment Product and Services
2.9.4 Lupin Chronic Myeloid Leukemia Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.10 IL-YANG PHARM CO. LTD.
2.10.1 IL-YANG PHARM CO. LTD. Details
2.10.2 IL-YANG PHARM CO. LTD. Major Business
2.10.3 IL-YANG PHARM CO. LTD. Chronic Myeloid Leukemia Treatment Product and Services
2.10.4 IL-YANG PHARM CO. LTD. Chronic Myeloid Leukemia Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.11 Million Health Pharmaceuticals
2.11.1 Million Health Pharmaceuticals Details
2.11.2 Million Health Pharmaceuticals Major Business
2.11.3 Million Health Pharmaceuticals Chronic Myeloid Leukemia Treatment Product and Services
2.11.4 Million Health Pharmaceuticals Chronic Myeloid Leukemia Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.12 Celon Labs
2.12.1 Celon Labs Details
2.12.2 Celon Labs Major Business
2.12.3 Celon Labs Chronic Myeloid Leukemia Treatment Product and Services
2.12.4 Celon Labs Chronic Myeloid Leukemia Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
3 Chronic Myeloid Leukemia Treatment Breakdown Data by Manufacturer
3.1 Global Chronic Myeloid Leukemia Treatment Sales in Volume by Manufacturer (2019, 2020, 2021, and 2022)
3.2 Global Chronic Myeloid Leukemia Treatment Revenue by Manufacturer (2019, 2020, 2021, and 2022)
3.3 Key Manufacturer Market Position in Chronic Myeloid Leukemia Treatment
3.4 Market Concentration Rate
3.4.1 Top 3 Chronic Myeloid Leukemia Treatment Manufacturer Market Share in 2021
3.4.2 Top 6 Chronic Myeloid Leukemia Treatment Manufacturer Market Share in 2021
3.5 Global Chronic Myeloid Leukemia Treatment Production Capacity by Company: 2021 VS 2022
3.6 Manufacturer by Geography: Head Office and Chronic Myeloid Leukemia Treatment Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Chronic Myeloid Leukemia Treatment Market Size by Region
4.1.1 Global Chronic Myeloid Leukemia Treatment Sales in Volume by Region (2017-2028)
4.1.2 Global Chronic Myeloid Leukemia Treatment Revenue by Region (2017-2028)
4.2 North America Chronic Myeloid Leukemia Treatment Revenue (2017-2028)
4.3 Europe Chronic Myeloid Leukemia Treatment Revenue (2017-2028)
4.4 Asia-Pacific Chronic Myeloid Leukemia Treatment Revenue (2017-2028)
4.5 South America Chronic Myeloid Leukemia Treatment Revenue (2017-2028)
4.6 Middle East and Africa Chronic Myeloid Leukemia Treatment Revenue (2017-2028)
5 Market Segment by Type
5.1 Global Chronic Myeloid Leukemia Treatment Sales in Volume by Type (2017-2028)
5.2 Global Chronic Myeloid Leukemia Treatment Revenue by Type (2017-2028)
5.3 Global Chronic Myeloid Leukemia Treatment Price by Type (2017-2028)
6 Market Segment by Application
6.1 Global Chronic Myeloid Leukemia Treatment Sales in Volume by Application (2017-2028)
6.2 Global Chronic Myeloid Leukemia Treatment Revenue by Application (2017-2028)
6.3 Global Chronic Myeloid Leukemia Treatment Price by Application (2017-2028)
7 North America by Country, by Type, and by Application
7.1 North America Chronic Myeloid Leukemia Treatment Sales by Type (2017-2028)
7.2 North America Chronic Myeloid Leukemia Treatment Sales by Application (2017-2028)
7.3 North America Chronic Myeloid Leukemia Treatment Market Size by Country
7.3.1 North America Chronic Myeloid Leukemia Treatment Sales in Volume by Country (2017-2028)
7.3.2 North America Chronic Myeloid Leukemia Treatment Revenue by Country (2017-2028)
7.3.3 United States Market Size and Forecast (2017-2028)
7.3.4 Canada Market Size and Forecast (2017-2028)
7.3.5 Mexico Market Size and Forecast (2017-2028)
8 Europe by Country, by Type, and by Application
8.1 Europe Chronic Myeloid Leukemia Treatment Sales by Type (2017-2028)
8.2 Europe Chronic Myeloid Leukemia Treatment Sales by Application (2017-2028)
8.3 Europe Chronic Myeloid Leukemia Treatment Market Size by Country
8.3.1 Europe Chronic Myeloid Leukemia Treatment Sales in Volume by Country (2017-2028)
8.3.2 Europe Chronic Myeloid Leukemia Treatment Revenue by Country (2017-2028)
8.3.3 Germany Market Size and Forecast (2017-2028)
8.3.4 France Market Size and Forecast (2017-2028)
8.3.5 United Kingdom Market Size and Forecast (2017-2028)
8.3.6 Russia Market Size and Forecast (2017-2028)
8.3.7 Italy Market Size and Forecast (2017-2028)
9 Asia-Pacific by Region, by Type, and by Application
9.1 Asia-Pacific Chronic Myeloid Leukemia Treatment Sales by Type (2017-2028)
9.2 Asia-Pacific Chronic Myeloid Leukemia Treatment Sales by Application (2017-2028)
9.3 Asia-Pacific Chronic Myeloid Leukemia Treatment Market Size by Region
9.3.1 Asia-Pacific Chronic Myeloid Leukemia Treatment Sales in Volume by Region (2017-2028)
9.3.2 Asia-Pacific Chronic Myeloid Leukemia Treatment Revenue by Region (2017-2028)
9.3.3 China Market Size and Forecast (2017-2028)
9.3.4 Japan Market Size and Forecast (2017-2028)
9.3.5 Korea Market Size and Forecast (2017-2028)
9.3.6 India Market Size and Forecast (2017-2028)
9.3.7 Southeast Asia Market Size and Forecast (2017-2028)
9.3.8 Australia Market Size and Forecast (2017-2028)
10 South America by Region, by Type, and by Application
10.1 South America Chronic Myeloid Leukemia Treatment Sales by Type (2017-2028)
10.2 South America Chronic Myeloid Leukemia Treatment Sales by Application (2017-2028)
10.3 South America Chronic Myeloid Leukemia Treatment Market Size by Country
10.3.1 South America Chronic Myeloid Leukemia Treatment Sales in Volume by Country (2017-2028)
10.3.2 South America Chronic Myeloid Leukemia Treatment Revenue by Country (2017-2028)
10.3.3 Brazil Market Size and Forecast (2017-2028)
10.3.4 Argentina Market Size and Forecast (2017-2028)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Chronic Myeloid Leukemia Treatment Sales by Type (2017-2028)
11.2 Middle East & Africa Chronic Myeloid Leukemia Treatment Sales by Application (2017-2028)
11.3 Middle East & Africa Chronic Myeloid Leukemia Treatment Market Size by Country
11.3.1 Middle East & Africa Chronic Myeloid Leukemia Treatment Sales in Volume by Country (2017-2028)
11.3.2 Middle East & Africa Chronic Myeloid Leukemia Treatment Revenue by Country (2017-2028)
11.3.3 Turkey Market Size and Forecast (2017-2028)
11.3.4 Egypt Market Size and Forecast (2017-2028)
11.3.5 Saudi Arabia Market Size and Forecast (2017-2028)
11.3.6 South Africa Market Size and Forecast (2017-2028)
12 Raw Material and Industry Chain
12.1 Raw Material of Chronic Myeloid Leukemia Treatment and Key Manufacturers
12.2 Manufacturing Costs Percentage of Chronic Myeloid Leukemia Treatment
12.3 Chronic Myeloid Leukemia Treatment Production Process
12.4 Chronic Myeloid Leukemia Treatment Industrial Chain
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Chronic Myeloid Leukemia Treatment Typical Distributors
13.3 Chronic Myeloid Leukemia Treatment Typical Customers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Research Process and Data Source
15.3 Disclaimer

List of Tables
Table 1. Global Chronic Myeloid Leukemia Treatment Revenue by Type, (USD Million), 2017 & 2021 & 2028
Table 2. Global Chronic Myeloid Leukemia Treatment Revenue by Application, (USD Million), 2017 & 2021 & 2028
Table 3. Teva Pharmaceutical Industries Ltd Basic Information, Manufacturing Base and Competitors
Table 4. Teva Pharmaceutical Industries Ltd Major Business
Table 5. Teva Pharmaceutical Industries Ltd Chronic Myeloid Leukemia Treatment Product and Services
Table 6. Teva Pharmaceutical Industries Ltd Chronic Myeloid Leukemia Treatment Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 7. F. Hoffmann-La Roche Ltd. Basic Information, Manufacturing Base and Competitors
Table 8. F. Hoffmann-La Roche Ltd. Major Business
Table 9. F. Hoffmann-La Roche Ltd. Chronic Myeloid Leukemia Treatment Product and Services
Table 10. F. Hoffmann-La Roche Ltd. Chronic Myeloid Leukemia Treatment Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 11. Novartis AG Basic Information, Manufacturing Base and Competitors
Table 12. Novartis AG Major Business
Table 13. Novartis AG Chronic Myeloid Leukemia Treatment Product and Services
Table 14. Novartis AG Chronic Myeloid Leukemia Treatment Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 15. Bristol-Myers Squibb Company Basic Information, Manufacturing Base and Competitors
Table 16. Bristol-Myers Squibb Company Major Business
Table 17. Bristol-Myers Squibb Company Chronic Myeloid Leukemia Treatment Product and Services
Table 18. Bristol-Myers Squibb Company Chronic Myeloid Leukemia Treatment Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 19. Pfizer Inc. Basic Information, Manufacturing Base and Competitors
Table 20. Pfizer Inc. Major Business
Table 21. Pfizer Inc. Chronic Myeloid Leukemia Treatment Product and Services
Table 22. Pfizer Inc. Chronic Myeloid Leukemia Treatment Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 23. Takeda Pharmaceutical Company Limited Basic Information, Manufacturing Base and Competitors
Table 24. Takeda Pharmaceutical Company Limited Major Business
Table 25. Takeda Pharmaceutical Company Limited Chronic Myeloid Leukemia Treatment Product and Services
Table 26. Takeda Pharmaceutical Company Limited Chronic Myeloid Leukemia Treatment Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 27. Innovent Biologics, Inc. Basic Information, Manufacturing Base and Competitors
Table 28. Innovent Biologics, Inc. Major Business
Table 29. Innovent Biologics, Inc. Chronic Myeloid Leukemia Treatment Product and Services
Table 30. Innovent Biologics, Inc. Chronic Myeloid Leukemia Treatment Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 31. Viatris Inc. (Mylan N.V.) Basic Information, Manufacturing Base and Competitors
Table 32. Viatris Inc. (Mylan N.V.) Major Business
Table 33. Viatris Inc. (Mylan N.V.) Chronic Myeloid Leukemia Treatment Product and Services
Table 34. Viatris Inc. (Mylan N.V.) Chronic Myeloid Leukemia Treatment Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 35. Lupin Basic Information, Manufacturing Base and Competitors
Table 36. Lupin Major Business
Table 37. Lupin Chronic Myeloid Leukemia Treatment Product and Services
Table 38. Lupin Chronic Myeloid Leukemia Treatment Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 39. IL-YANG PHARM CO. LTD. Basic Information, Manufacturing Base and Competitors
Table 40. IL-YANG PHARM CO. LTD. Major Business
Table 41. IL-YANG PHARM CO. LTD. Chronic Myeloid Leukemia Treatment Product and Services
Table 42. IL-YANG PHARM CO. LTD. Chronic Myeloid Leukemia Treatment Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 43. Million Health Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 44. Million Health Pharmaceuticals Major Business
Table 45. Million Health Pharmaceuticals Chronic Myeloid Leukemia Treatment Product and Services
Table 46. Million Health Pharmaceuticals Chronic Myeloid Leukemia Treatment Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 47. Celon Labs Basic Information, Manufacturing Base and Competitors
Table 48. Celon Labs Major Business
Table 49. Celon Labs Chronic Myeloid Leukemia Treatment Product and Services
Table 50. Celon Labs Chronic Myeloid Leukemia Treatment Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 51. Global Chronic Myeloid Leukemia Treatment Sales by Manufacturer (2019, 2020, 2021, and 2022) & (K Units)
Table 52. Global Chronic Myeloid Leukemia Treatment Revenue by Manufacturer (2019, 2020, 2021, and 2022) & (USD Million)
Table 53. Market Position of Manufacturers in Chronic Myeloid Leukemia Treatment, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2021
Table 54. Global Chronic Myeloid Leukemia Treatment Production Capacity by Company, (K Units): 2020 VS 2021
Table 55. Head Office and Chronic Myeloid Leukemia Treatment Production Site of Key Manufacturer
Table 56. Chronic Myeloid Leukemia Treatment New Entrant and Capacity Expansion Plans
Table 57. Chronic Myeloid Leukemia Treatment Mergers & Acquisitions in the Past Five Years
Table 58. Global Chronic Myeloid Leukemia Treatment Sales by Region (2017-2022) & (K Units)
Table 59. Global Chronic Myeloid Leukemia Treatment Sales by Region (2023-2028) & (K Units)
Table 60. Global Chronic Myeloid Leukemia Treatment Revenue by Region (2017-2022) & (USD Million)
Table 61. Global Chronic Myeloid Leukemia Treatment Revenue by Region (2023-2028) & (USD Million)
Table 62. Global Chronic Myeloid Leukemia Treatment Sales by Type (2017-2022) & (K Units)
Table 63. Global Chronic Myeloid Leukemia Treatment Sales by Type (2023-2028) & (K Units)
Table 64. Global Chronic Myeloid Leukemia Treatment Revenue by Type (2017-2022) & (USD Million)
Table 65. Global Chronic Myeloid Leukemia Treatment Revenue by Type (2023-2028) & (USD Million)
Table 66. Global Chronic Myeloid Leukemia Treatment Price by Type (2017-2022) & (US$/Unit)
Table 67. Global Chronic Myeloid Leukemia Treatment Price by Type (2023-2028) & (US$/Unit)
Table 68. Global Chronic Myeloid Leukemia Treatment Sales by Application (2017-2022) & (K Units)
Table 69. Global Chronic Myeloid Leukemia Treatment Sales by Application (2023-2028) & (K Units)
Table 70. Global Chronic Myeloid Leukemia Treatment Revenue by Application (2017-2022) & (USD Million)
Table 71. Global Chronic Myeloid Leukemia Treatment Revenue by Application (2023-2028) & (USD Million)
Table 72. Global Chronic Myeloid Leukemia Treatment Price by Application (2017-2022) & (US$/Unit)
Table 73. Global Chronic Myeloid Leukemia Treatment Price by Application (2023-2028) & (US$/Unit)
Table 74. North America Chronic Myeloid Leukemia Treatment Sales by Country (2017-2022) & (K Units)
Table 75. North America Chronic Myeloid Leukemia Treatment Sales by Country (2023-2028) & (K Units)
Table 76. North America Chronic Myeloid Leukemia Treatment Revenue by Country (2017-2022) & (USD Million)
Table 77. North America Chronic Myeloid Leukemia Treatment Revenue by Country (2023-2028) & (USD Million)
Table 78. North America Chronic Myeloid Leukemia Treatment Sales by Type (2017-2022) & (K Units)
Table 79. North America Chronic Myeloid Leukemia Treatment Sales by Type (2023-2028) & (K Units)
Table 80. North America Chronic Myeloid Leukemia Treatment Sales by Application (2017-2022) & (K Units)
Table 81. North America Chronic Myeloid Leukemia Treatment Sales by Application (2023-2028) & (K Units)
Table 82. Europe Chronic Myeloid Leukemia Treatment Sales by Country (2017-2022) & (K Units)
Table 83. Europe Chronic Myeloid Leukemia Treatment Sales by Country (2023-2028) & (K Units)
Table 84. Europe Chronic Myeloid Leukemia Treatment Revenue by Country (2017-2022) & (USD Million)
Table 85. Europe Chronic Myeloid Leukemia Treatment Revenue by Country (2023-2028) & (USD Million)
Table 86. Europe Chronic Myeloid Leukemia Treatment Sales by Type (2017-2022) & (K Units)
Table 87. Europe Chronic Myeloid Leukemia Treatment Sales by Type (2023-2028) & (K Units)
Table 88. Europe Chronic Myeloid Leukemia Treatment Sales by Application (2017-2022) & (K Units)
Table 89. Europe Chronic Myeloid Leukemia Treatment Sales by Application (2023-2028) & (K Units)
Table 90. Asia-Pacific Chronic Myeloid Leukemia Treatment Sales by Region (2017-2022) & (K Units)
Table 91. Asia-Pacific Chronic Myeloid Leukemia Treatment Sales by Region (2023-2028) & (K Units)
Table 92. Asia-Pacific Chronic Myeloid Leukemia Treatment Revenue by Region (2017-2022) & (USD Million)
Table 93. Asia-Pacific Chronic Myeloid Leukemia Treatment Revenue by Region (2023-2028) & (USD Million)
Table 94. Asia-Pacific Chronic Myeloid Leukemia Treatment Sales by Type (2017-2022) & (K Units)
Table 95. Asia-Pacific Chronic Myeloid Leukemia Treatment Sales by Type (2023-2028) & (K Units)
Table 96. Asia-Pacific Chronic Myeloid Leukemia Treatment Sales by Application (2017-2022) & (K Units)
Table 97. Asia-Pacific Chronic Myeloid Leukemia Treatment Sales by Application (2023-2028) & (K Units)
Table 98. South America Chronic Myeloid Leukemia Treatment Sales by Country (2017-2022) & (K Units)
Table 99. South America Chronic Myeloid Leukemia Treatment Sales by Country (2023-2028) & (K Units)
Table 100. South America Chronic Myeloid Leukemia Treatment Revenue by Country (2017-2022) & (USD Million)
Table 101. South America Chronic Myeloid Leukemia Treatment Revenue by Country (2023-2028) & (USD Million)
Table 102. South America Chronic Myeloid Leukemia Treatment Sales by Type (2017-2022) & (K Units)
Table 103. South America Chronic Myeloid Leukemia Treatment Sales by Type (2023-2028) & (K Units)
Table 104. South America Chronic Myeloid Leukemia Treatment Sales by Application (2017-2022) & (K Units)
Table 105. South America Chronic Myeloid Leukemia Treatment Sales by Application (2023-2028) & (K Units)
Table 106. Middle East & Africa Chronic Myeloid Leukemia Treatment Sales by Region (2017-2022) & (K Units)
Table 107. Middle East & Africa Chronic Myeloid Leukemia Treatment Sales by Region (2023-2028) & (K Units)
Table 108. Middle East & Africa Chronic Myeloid Leukemia Treatment Revenue by Region (2017-2022) & (USD Million)
Table 109. Middle East & Africa Chronic Myeloid Leukemia Treatment Revenue by Region (2023-2028) & (USD Million)
Table 110. Middle East & Africa Chronic Myeloid Leukemia Treatment Sales by Type (2017-2022) & (K Units)
Table 111. Middle East & Africa Chronic Myeloid Leukemia Treatment Sales by Type (2023-2028) & (K Units)
Table 112. Middle East & Africa Chronic Myeloid Leukemia Treatment Sales by Application (2017-2022) & (K Units)
Table 113. Middle East & Africa Chronic Myeloid Leukemia Treatment Sales by Application (2023-2028) & (K Units)
Table 114. Chronic Myeloid Leukemia Treatment Raw Material
Table 115. Key Manufacturers of Chronic Myeloid Leukemia Treatment Raw Materials
Table 116. Direct Channel Pros & Cons
Table 117. Indirect Channel Pros & Cons
Table 118. Chronic Myeloid Leukemia Treatment Typical Distributors
Table 119. Chronic Myeloid Leukemia Treatment Typical Customers
List of Figures
Figure 1. Chronic Myeloid Leukemia Treatment Picture
Figure 2. Global Chronic Myeloid Leukemia Treatment Revenue Market Share by Type in 2021
Figure 3. Tablet
Figure 4. Solution
Figure 5. Capsule
Figure 6. Global Chronic Myeloid Leukemia Treatment Revenue Market Share by Application in 2021
Figure 7. Hospital Pharmacies
Figure 8. Retail Pharmacies
Figure 9. Online Pharmacies
Figure 10. Global Chronic Myeloid Leukemia Treatment Revenue, (USD Million) & (K Units): 2017 & 2021 & 2028
Figure 11. Global Chronic Myeloid Leukemia Treatment Revenue and Forecast (2017-2028) & (USD Million)
Figure 12. Global Chronic Myeloid Leukemia Treatment Sales (2017-2028) & (K Units)
Figure 13. Global Chronic Myeloid Leukemia Treatment Price (2017-2028) & (US$/Unit)
Figure 14. Global Chronic Myeloid Leukemia Treatment Production Capacity (2017-2028) & (K Units)
Figure 15. Global Chronic Myeloid Leukemia Treatment Production Capacity by Geographic Region: 2022 VS 2028
Figure 16. Chronic Myeloid Leukemia Treatment Market Drivers
Figure 17. Chronic Myeloid Leukemia Treatment Market Restraints
Figure 18. Chronic Myeloid Leukemia Treatment Market Trends
Figure 19. Global Chronic Myeloid Leukemia Treatment Sales Market Share by Manufacturer in 2021
Figure 20. Global Chronic Myeloid Leukemia Treatment Revenue Market Share by Manufacturer in 2021
Figure 21. Chronic Myeloid Leukemia Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2021
Figure 22. Top 3 Chronic Myeloid Leukemia Treatment Manufacturer (Revenue) Market Share in 2021
Figure 23. Top 6 Chronic Myeloid Leukemia Treatment Manufacturer (Revenue) Market Share in 2021
Figure 24. Global Chronic Myeloid Leukemia Treatment Sales Market Share by Region (2017-2028)
Figure 25. Global Chronic Myeloid Leukemia Treatment Revenue Market Share by Region (2017-2028)
Figure 26. North America Chronic Myeloid Leukemia Treatment Revenue (2017-2028) & (USD Million)
Figure 27. Europe Chronic Myeloid Leukemia Treatment Revenue (2017-2028) & (USD Million)
Figure 28. Asia-Pacific Chronic Myeloid Leukemia Treatment Revenue (2017-2028) & (USD Million)
Figure 29. South America Chronic Myeloid Leukemia Treatment Revenue (2017-2028) & (USD Million)
Figure 30. Middle East & Africa Chronic Myeloid Leukemia Treatment Revenue (2017-2028) & (USD Million)
Figure 31. Global Chronic Myeloid Leukemia Treatment Sales Market Share by Type (2017-2028)
Figure 32. Global Chronic Myeloid Leukemia Treatment Revenue Market Share by Type (2017-2028)
Figure 33. Global Chronic Myeloid Leukemia Treatment Price by Type (2017-2028) & (US$/Unit)
Figure 34. Global Chronic Myeloid Leukemia Treatment Sales Market Share by Application (2017-2028)
Figure 35. Global Chronic Myeloid Leukemia Treatment Revenue Market Share by Application (2017-2028)
Figure 36. Global Chronic Myeloid Leukemia Treatment Price by Application (2017-2028) & (US$/Unit)
Figure 37. North America Chronic Myeloid Leukemia Treatment Sales Market Share by Type (2017-2028)
Figure 38. North America Chronic Myeloid Leukemia Treatment Sales Market Share by Application (2017-2028)
Figure 39. North America Chronic Myeloid Leukemia Treatment Sales Market Share by Country (2017-2028)
Figure 40. North America Chronic Myeloid Leukemia Treatment Revenue Market Share by Country (2017-2028)
Figure 41. United States Chronic Myeloid Leukemia Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 42. Canada Chronic Myeloid Leukemia Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 43. Mexico Chronic Myeloid Leukemia Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 44. Europe Chronic Myeloid Leukemia Treatment Sales Market Share by Type (2017-2028)
Figure 45. Europe Chronic Myeloid Leukemia Treatment Sales Market Share by Application (2017-2028)
Figure 46. Europe Chronic Myeloid Leukemia Treatment Sales Market Share by Country (2017-2028)
Figure 47. Europe Chronic Myeloid Leukemia Treatment Revenue Market Share by Country (2017-2028)
Figure 48. Germany Chronic Myeloid Leukemia Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 49. France Chronic Myeloid Leukemia Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 50. United Kingdom Chronic Myeloid Leukemia Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 51. Russia Chronic Myeloid Leukemia Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 52. Italy Chronic Myeloid Leukemia Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 53. Asia-Pacific Chronic Myeloid Leukemia Treatment Sales Market Share by Region (2017-2028)
Figure 54. Asia-Pacific Chronic Myeloid Leukemia Treatment Sales Market Share by Application (2017-2028)
Figure 55. Asia-Pacific Chronic Myeloid Leukemia Treatment Sales Market Share by Region (2017-2028)
Figure 56. Asia-Pacific Chronic Myeloid Leukemia Treatment Revenue Market Share by Region (2017-2028)
Figure 57. China Chronic Myeloid Leukemia Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 58. Japan Chronic Myeloid Leukemia Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 59. Korea Chronic Myeloid Leukemia Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 60. India Chronic Myeloid Leukemia Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 61. Southeast Asia Chronic Myeloid Leukemia Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 62. Australia Chronic Myeloid Leukemia Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 63. South America Chronic Myeloid Leukemia Treatment Sales Market Share by Type (2017-2028)
Figure 64. South America Chronic Myeloid Leukemia Treatment Sales Market Share by Application (2017-2028)
Figure 65. South America Chronic Myeloid Leukemia Treatment Sales Market Share by Country (2017-2028)
Figure 66. South America Chronic Myeloid Leukemia Treatment Revenue Market Share by Country (2017-2028)
Figure 67. Brazil Chronic Myeloid Leukemia Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 68. Argentina Chronic Myeloid Leukemia Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 69. Middle East & Africa Chronic Myeloid Leukemia Treatment Sales Market Share by Type (2017-2028)
Figure 70. Middle East & Africa Chronic Myeloid Leukemia Treatment Sales Market Share by Application (2017-2028)
Figure 71. Middle East & Africa Chronic Myeloid Leukemia Treatment Sales Market Share by Region (2017-2028)
Figure 72. Middle East & Africa Chronic Myeloid Leukemia Treatment Revenue Market Share by Region (2017-2028)
Figure 73. Turkey Chronic Myeloid Leukemia Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 74. Egypt Chronic Myeloid Leukemia Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 75. Saudi Arabia Chronic Myeloid Leukemia Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 76. South Africa Chronic Myeloid Leukemia Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 77. Manufacturing Cost Structure Analysis of Chronic Myeloid Leukemia Treatment in 2021
Figure 78. Manufacturing Process Analysis of Chronic Myeloid Leukemia Treatment
Figure 79. Chronic Myeloid Leukemia Treatment Industrial Chain
Figure 80. Sales Channel: Direct Channel vs Indirect Channel
Figure 81. Methodology
Figure 82. Research Process and Data Source


*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • 急性骨髄性白血病（AML）バイオマーカー検査の世界市場2023年：遺伝性急性骨髄性白血病（AML）バイオマーカー、エピジェネティック急性骨髄性白血病（AML）バイオマーカー、プロテオーム性急性骨髄性白血病（AML）バイオマーカー
  • 慢性呼吸器疾患治療のグローバル市場展望 2023年-2029年：コルチコステロイド、気管支拡張剤、モノクローナル抗体、抗生物質、粘液溶解剤、ロイコトリエン修飾薬、その他
  • 世界の慢性閉塞性肺疾患治療薬市場2022年：市場規模予測（～2028年）
  • 慢性完全閉塞（CTO）用装置のグローバル市場展望 2023年-2029年：マイクロカテーテル、ガイドワイヤー、クロッシング装置、リエントリー装置
  • 急性＆慢性感染創傷ケア包帯のグローバル市場展望 2023年-2029年：フォームドレッシング、ハイドロコロイドドレッシング、フィルムドレッシング、アルギン酸塩ドレッシング、ハイドロゲルドレッシング、コラーゲンドレッシング、その他
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(GIR22NO19231 )"世界の慢性骨髄性白血病治療市場2022年：市場規模予測（～2028年）" (英文：Global Chronic Myeloid Leukemia Treatment Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028)はGlobalInfoResearch社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。